APO Research
Talk to an analyst

APO RESEARCH · REPORT

Overactive Bladder Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Overactive Bladder Drug Industry Research Report 2026

20 December 2025126 pages

Choose your research edition.

Industry ResearchOveractive Bladder Drug Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Overactive Bladder Drug Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Overactive Bladder Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Overactive Bladder Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Overactive Bladder Drug Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Overactive Bladder Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Overactive Bladder Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Overactive Bladder Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Overactive Bladder Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Overactive Bladder Drug include Allergan, Plc (Ireland), Apotex, Inc. (Canada), Astellas Pharma, Inc. (Japan), Aurobindo Pharma Limited (India), Cogentix Medical, Inc. (US), Endo International plc (Ireland), Hisamitsu Pharmaceutical Co., Inc. (Japan), Medtronic plc (Ireland) and Pfizer, Inc. (US), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Overactive Bladder Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Overactive Bladder Drug Market by Company

Allergan, Plc (Ireland)

Apotex, Inc. (Canada)

Astellas Pharma, Inc. (Japan)

Aurobindo Pharma Limited (India)

Cogentix Medical, Inc. (US)

Endo International plc (Ireland)

Hisamitsu Pharmaceutical Co., Inc. (Japan)

Medtronic plc (Ireland)

Pfizer, Inc. (US)

Mylan N.V. (US)

Sanofi (France)

Teva Pharmaceutical Industries Limited (Israel)

Overactive Bladder Drug Segment by Type

Tolterodine

Solifenacin

Trospium

Anticholinergics

Fesoterodine

Darifenacin

Oxybutynin

Others

Overactive Bladder Drug Segment by Application

Idiopathic Bladder Overactivity

Neurogenic Bladder Overactivity

Overactive Bladder Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Overactive Bladder Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Overactive Bladder Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Overactive Bladder Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Overactive Bladder Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Overactive Bladder Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Overactive Bladder Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Overactive Bladder Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Overactive Bladder Drug Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Overactive Bladder Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Overactive Bladder Drug Revenue of Manufacturers (2021-2026) Table 9. Global Overactive Bladder Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Overactive Bladder Drug Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Overactive Bladder Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Overactive Bladder Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Overactive Bladder Drug, Product Type & Application Table 14. Global Overactive Bladder Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Overactive Bladder Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Allergan, Plc (Ireland) Company Information Table 19. Allergan, Plc (Ireland) Business Overview Table 20. Allergan, Plc (Ireland) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Allergan, Plc (Ireland) Overactive Bladder Drug Product Portfolio Table 22. Allergan, Plc (Ireland) Recent Developments Table 23. Apotex, Inc. (Canada) Company Information Table 24. Apotex, Inc. (Canada) Business Overview Table 25. Apotex, Inc. (Canada) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Apotex, Inc. (Canada) Overactive Bladder Drug Product Portfolio Table 27. Apotex, Inc. (Canada) Recent Developments Table 28. Astellas Pharma, Inc. (Japan) Company Information Table 29. Astellas Pharma, Inc. (Japan) Business Overview Table 30. Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Product Portfolio Table 32. Astellas Pharma, Inc. (Japan) Recent Developments Table 33. Aurobindo Pharma Limited (India) Company Information Table 34. Aurobindo Pharma Limited (India) Business Overview Table 35. Aurobindo Pharma Limited (India) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Aurobindo Pharma Limited (India) Overactive Bladder Drug Product Portfolio Table 37. Aurobindo Pharma Limited (India) Recent Developments Table 38. Cogentix Medical, Inc. (US) Company Information Table 39. Cogentix Medical, Inc. (US) Business Overview Table 40. Cogentix Medical, Inc. (US) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Cogentix Medical, Inc. (US) Overactive Bladder Drug Product Portfolio Table 42. Cogentix Medical, Inc. (US) Recent Developments Table 43. Endo International plc (Ireland) Company Information Table 44. Endo International plc (Ireland) Business Overview Table 45. Endo International plc (Ireland) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Endo International plc (Ireland) Overactive Bladder Drug Product Portfolio Table 47. Endo International plc (Ireland) Recent Developments Table 48. Hisamitsu Pharmaceutical Co., Inc. (Japan) Company Information Table 49. Hisamitsu Pharmaceutical Co., Inc. (Japan) Business Overview Table 50. Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Product Portfolio Table 52. Hisamitsu Pharmaceutical Co., Inc. (Japan) Recent Developments Table 53. Medtronic plc (Ireland) Company Information Table 54. Medtronic plc (Ireland) Business Overview Table 55. Medtronic plc (Ireland) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Medtronic plc (Ireland) Overactive Bladder Drug Product Portfolio Table 57. Medtronic plc (Ireland) Recent Developments Table 58. Pfizer, Inc. (US) Company Information Table 59. Pfizer, Inc. (US) Business Overview Table 60. Pfizer, Inc. (US) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Pfizer, Inc. (US) Overactive Bladder Drug Product Portfolio Table 62. Pfizer, Inc. (US) Recent Developments Table 63. Mylan N.V. (US) Company Information Table 64. Mylan N.V. (US) Business Overview Table 65. Mylan N.V. (US) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Mylan N.V. (US) Overactive Bladder Drug Product Portfolio Table 67. Mylan N.V. (US) Recent Developments Table 68. Sanofi (France) Company Information Table 69. Sanofi (France) Business Overview Table 70. Sanofi (France) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Sanofi (France) Overactive Bladder Drug Product Portfolio Table 72. Sanofi (France) Recent Developments Table 73. Teva Pharmaceutical Industries Limited (Israel) Company Information Table 74. Teva Pharmaceutical Industries Limited (Israel) Business Overview Table 75. Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Product Portfolio Table 77. Teva Pharmaceutical Industries Limited (Israel) Recent Developments Table 78. Global Overactive Bladder Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 79. Global Overactive Bladder Drug Sales by Region (2021-2026) & (K Units) Table 80. Global Overactive Bladder Drug Sales Market Share by Region (2021-2026) Table 81. Global Overactive Bladder Drug Sales by Region (2027-2032) & (K Units) Table 82. Global Overactive Bladder Drug Sales Market Share by Region (2027-2032) Table 83. Global Overactive Bladder Drug Revenue by Region (2021-2026) & (US$ Million) Table 84. Global Overactive Bladder Drug Revenue Market Share by Region (2021-2026) Table 85. Global Overactive Bladder Drug Revenue by Region (2027-2032) & (US$ Million) Table 86. Global Overactive Bladder Drug Revenue Market Share by Region (2027-2032) Table 87. North America Overactive Bladder Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. North America Overactive Bladder Drug Sales by Country (2021-2026) & (K Units) Table 89. North America Overactive Bladder Drug Sales by Country (2027-2032) & (K Units) Table 90. North America Overactive Bladder Drug Revenue by Country (2021-2026) & (US$ Million) Table 91. North America Overactive Bladder Drug Revenue by Country (2027-2032) & (US$ Million) Table 92. Europe Overactive Bladder Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. Europe Overactive Bladder Drug Sales by Country (2021-2026) & (K Units) Table 94. Europe Overactive Bladder Drug Sales by Country (2027-2032) & (K Units) Table 95. Europe Overactive Bladder Drug Revenue by Country (2021-2026) & (US$ Million) Table 96. Europe Overactive Bladder Drug Revenue by Country (2027-2032) & (US$ Million) Table 97. Asia Pacific Overactive Bladder Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Asia Pacific Overactive Bladder Drug Sales by Country (2021-2026) & (K Units) Table 99. Asia Pacific Overactive Bladder Drug Sales by Country (2027-2032) & (K Units) Table 100. Asia Pacific Overactive Bladder Drug Revenue by Country (2021-2026) & (US$ Million) Table 101. Asia Pacific Overactive Bladder Drug Revenue by Country (2027-2032) & (US$ Million) Table 102. South America Overactive Bladder Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. South America Overactive Bladder Drug Sales by Country (2021-2026) & (K Units) Table 104. South America Overactive Bladder Drug Sales by Country (2027-2032) & (K Units) Table 105. South America Overactive Bladder Drug Revenue by Country (2021-2026) & (US$ Million) Table 106. South America Overactive Bladder Drug Revenue by Country (2027-2032) & (US$ Million) Table 107. Middle East and Africa Overactive Bladder Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Middle East and Africa Overactive Bladder Drug Sales by Country (2021-2026) & (K Units) Table 109. Middle East and Africa Overactive Bladder Drug Sales by Country (2027-2032) & (K Units) Table 110. Middle East and Africa Overactive Bladder Drug Revenue by Country (2021-2026) & (US$ Million) Table 111. Middle East and Africa Overactive Bladder Drug Revenue by Country (2027-2032) & (US$ Million) Table 112. Global Overactive Bladder Drug Sales by Type (2021-2026) & (K Units) Table 113. Global Overactive Bladder Drug Sales by Type (2027-2032) & (K Units) Table 114. Global Overactive Bladder Drug Sales Market Share by Type (2021-2026) Table 115. Global Overactive Bladder Drug Sales Market Share by Type (2027-2032) Table 116. Global Overactive Bladder Drug Revenue by Type (2021-2026) & (US$ Million) Table 117. Global Overactive Bladder Drug Revenue by Type (2027-2032) & (US$ Million) Table 118. Global Overactive Bladder Drug Revenue Market Share by Type (2021-2026) Table 119. Global Overactive Bladder Drug Revenue Market Share by Type (2027-2032) Table 120. Global Overactive Bladder Drug Price by Type (2021-2026) & (US$/Unit) Table 121. Global Overactive Bladder Drug Price by Type (2027-2032) & (US$/Unit) Table 122. Global Overactive Bladder Drug Sales by Application (2021-2026) & (K Units) Table 123. Global Overactive Bladder Drug Sales by Application (2027-2032) & (K Units) Table 124. Global Overactive Bladder Drug Sales Market Share by Application (2021-2026) Table 125. Global Overactive Bladder Drug Sales Market Share by Application (2027-2032) Table 126. Global Overactive Bladder Drug Revenue by Application (2021-2026) & (US$ Million) Table 127. Global Overactive Bladder Drug Revenue by Application (2027-2032) & (US$ Million) Table 128. Global Overactive Bladder Drug Revenue Market Share by Application (2021-2026) Table 129. Global Overactive Bladder Drug Revenue Market Share by Application (2027-2032) Table 130. Global Overactive Bladder Drug Price by Application (2021-2026) & (US$/Unit) Table 131. Global Overactive Bladder Drug Price by Application (2027-2032) & (US$/Unit) Table 132. Key Raw Materials Table 133. Raw Materials Key Suppliers Table 134. Overactive Bladder Drug Distributors List Table 135. Overactive Bladder Drug Customers List Table 136. Overactive Bladder Drug Industry Trends Table 137. Overactive Bladder Drug Industry Drivers Table 138. Overactive Bladder Drug Industry Restraints Table 139. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Overactive Bladder Drug Product Image Figure 5. Global Overactive Bladder Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Overactive Bladder Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Overactive Bladder Drug Sales (2021-2032) & (K Units) Figure 8. Global Overactive Bladder Drug Average Price (US$/Unit) & (2021-2032) Figure 9. Tolterodine Product Image Figure 10. Solifenacin Product Image Figure 11. Trospium Product Image Figure 12. Anticholinergics Product Image Figure 13. Fesoterodine Product Image Figure 14. Darifenacin Product Image Figure 15. Oxybutynin Product Image Figure 16. Others Product Image Figure 17. Idiopathic Bladder Overactivity Product Image Figure 18. Neurogenic Bladder Overactivity Product Image Figure 19. Global Overactive Bladder Drug Revenue Share by Manufacturers in 2025 Figure 20. Global Manufacturers of Overactive Bladder Drug, Manufacturing Sites & Headquarters Figure 21. Global Top 5 and 10 Overactive Bladder Drug Players Market Share by Revenue in 2025 Figure 22. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Overactive Bladder Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 24. Global Overactive Bladder Drug Sales by Region in 2025 Figure 25. Global Overactive Bladder Drug Revenue by Region in 2025 Figure 26. North America Overactive Bladder Drug Market Size by Country in 2025 Figure 27. North America Overactive Bladder Drug Sales Market Share by Country (2021-2032) Figure 28. North America Overactive Bladder Drug Revenue Market Share by Country (2021-2032) Figure 29. United States Overactive Bladder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Canada Overactive Bladder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Europe Overactive Bladder Drug Market Size by Country in 2025 Figure 32. Europe Overactive Bladder Drug Sales Market Share by Country (2021-2032) Figure 33. Europe Overactive Bladder Drug Revenue Market Share by Country (2021-2032) Figure 34. Germany Overactive Bladder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. France Overactive Bladder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. U.K. Overactive Bladder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Italy Overactive Bladder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands Overactive Bladder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Asia Pacific Overactive Bladder Drug Market Size by Country in 2025 Figure 40. Asia Pacific Overactive Bladder Drug Sales Market Share by Country (2021-2032) Figure 41. Asia Pacific Overactive Bladder Drug Revenue Market Share by Country (2021-2032) Figure 42. China Overactive Bladder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Japan Overactive Bladder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. South Korea Overactive Bladder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. India Overactive Bladder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Australia Overactive Bladder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. China Taiwan Overactive Bladder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Southeast Asia Overactive Bladder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Overactive Bladder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. South America Overactive Bladder Drug Market Size by Country in 2025 Figure 51. South America Overactive Bladder Drug Sales Market Share by Country (2021-2032) Figure 52. South America Overactive Bladder Drug Revenue Market Share by Country (2021-2032) Figure 53. Mexico Overactive Bladder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Brazil Overactive Bladder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Overactive Bladder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Middle East and Africa Overactive Bladder Drug Market Size by Country in 2025 Figure 57. Middle East and Africa Overactive Bladder Drug Sales Market Share by Country (2021-2032) Figure 58. Middle East and Africa Overactive Bladder Drug Revenue Market Share by Country (2021-2032) Figure 59. Turkey Overactive Bladder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Saudi Arabia Overactive Bladder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. UAE Overactive Bladder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Global Overactive Bladder Drug Sales Market Share by Type (2021-2032) Figure 63. Global Overactive Bladder Drug Revenue Market Share by Type (2021-2032) Figure 64. Global Overactive Bladder Drug Price (US$/Unit) by Type (2021-2032) Figure 65. Global Overactive Bladder Drug Sales Market Share by Application (2021-2032) Figure 66. Global Overactive Bladder Drug Revenue Market Share by Application (2021-2032) Figure 67. Global Overactive Bladder Drug Price (US$/Unit) by Application (2021-2032) Figure 68. Overactive Bladder Drug Value Chain Figure 69. Overactive Bladder Drug Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Overactive Bladder Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • Tolterodine
  • Solifenacin
  • Trospium
  • Anticholinergics
  • Fesoterodine
  • Darifenacin
  • Oxybutynin
  • Others
Applications
  • Idiopathic Bladder Overactivity
  • Neurogenic Bladder Overactivity
Companies covered
  • Allergan, Plc (Ireland)
  • Apotex, Inc. (Canada)
  • Astellas Pharma, Inc. (Japan)
  • Aurobindo Pharma Limited (India)
  • Cogentix Medical, Inc. (US)
  • Endo International plc (Ireland)
  • Hisamitsu Pharmaceutical Co., Inc. (Japan)
  • Medtronic plc (Ireland)
  • Pfizer, Inc. (US)
  • Mylan N.V. (US)
  • Sanofi (France)
  • Teva Pharmaceutical Industries Limited (Israel)

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Overactive Bladder Drug Market Size (2021-2032)
  4. 2.2.2 Global Overactive Bladder Drug Sales (2021-2032)
  5. 2.2.3 Global Overactive Bladder Drug Market Average Price (2021-2032)
  6. 2.3 Overactive Bladder Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Tolterodine
  9. 2.3.3 Solifenacin
  10. 2.3.4 Trospium
  11. 2.3.5 Anticholinergics
  12. 2.3.6 Fesoterodine
  13. 2.3.7 Darifenacin
  14. 2.3.8 Oxybutynin
  15. 2.3.9 Others
  16. 2.4 Overactive Bladder Drug by Application
  17. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  18. 2.4.2 Idiopathic Bladder Overactivity
  19. 2.4.3 Neurogenic Bladder Overactivity
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Overactive Bladder Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Overactive Bladder Drug Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Overactive Bladder Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Overactive Bladder Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Overactive Bladder Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Overactive Bladder Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Overactive Bladder Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Overactive Bladder Drug, Established Date
  9. 3.9 Global Overactive Bladder Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Allergan, Plc (Ireland)
  2. 4.1.1 Allergan, Plc (Ireland) Company Information
  3. 4.1.2 Allergan, Plc (Ireland) Business Overview
  4. 4.1.3 Allergan, Plc (Ireland) Overactive Bladder Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Allergan, Plc (Ireland) Overactive Bladder Drug Product Portfolio
  6. 4.1.5 Allergan, Plc (Ireland) Recent Developments
  7. 4.2 Apotex, Inc. (Canada)
  8. 4.2.1 Apotex, Inc. (Canada) Company Information
  9. 4.2.2 Apotex, Inc. (Canada) Business Overview
  10. 4.2.3 Apotex, Inc. (Canada) Overactive Bladder Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Apotex, Inc. (Canada) Overactive Bladder Drug Product Portfolio
  12. 4.2.5 Apotex, Inc. (Canada) Recent Developments
  13. 4.3 Astellas Pharma, Inc. (Japan)
  14. 4.3.1 Astellas Pharma, Inc. (Japan) Company Information
  15. 4.3.2 Astellas Pharma, Inc. (Japan) Business Overview
  16. 4.3.3 Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Product Portfolio
  18. 4.3.5 Astellas Pharma, Inc. (Japan) Recent Developments
  19. 4.4 Aurobindo Pharma Limited (India)
  20. 4.4.1 Aurobindo Pharma Limited (India) Company Information
  21. 4.4.2 Aurobindo Pharma Limited (India) Business Overview
  22. 4.4.3 Aurobindo Pharma Limited (India) Overactive Bladder Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Aurobindo Pharma Limited (India) Overactive Bladder Drug Product Portfolio
  24. 4.4.5 Aurobindo Pharma Limited (India) Recent Developments
  25. 4.5 Cogentix Medical, Inc. (US)
  26. 4.5.1 Cogentix Medical, Inc. (US) Company Information
  27. 4.5.2 Cogentix Medical, Inc. (US) Business Overview
  28. 4.5.3 Cogentix Medical, Inc. (US) Overactive Bladder Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Cogentix Medical, Inc. (US) Overactive Bladder Drug Product Portfolio
  30. 4.5.5 Cogentix Medical, Inc. (US) Recent Developments
  31. 4.6 Endo International plc (Ireland)
  32. 4.6.1 Endo International plc (Ireland) Company Information
  33. 4.6.2 Endo International plc (Ireland) Business Overview
  34. 4.6.3 Endo International plc (Ireland) Overactive Bladder Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Endo International plc (Ireland) Overactive Bladder Drug Product Portfolio
  36. 4.6.5 Endo International plc (Ireland) Recent Developments
  37. 4.7 Hisamitsu Pharmaceutical Co., Inc. (Japan)
  38. 4.7.1 Hisamitsu Pharmaceutical Co., Inc. (Japan) Company Information
  39. 4.7.2 Hisamitsu Pharmaceutical Co., Inc. (Japan) Business Overview
  40. 4.7.3 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Product Portfolio
  42. 4.7.5 Hisamitsu Pharmaceutical Co., Inc. (Japan) Recent Developments
  43. 4.8 Medtronic plc (Ireland)
  44. 4.8.1 Medtronic plc (Ireland) Company Information
  45. 4.8.2 Medtronic plc (Ireland) Business Overview
  46. 4.8.3 Medtronic plc (Ireland) Overactive Bladder Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Medtronic plc (Ireland) Overactive Bladder Drug Product Portfolio
  48. 4.8.5 Medtronic plc (Ireland) Recent Developments
  49. 4.9 Pfizer, Inc. (US)
  50. 4.9.1 Pfizer, Inc. (US) Company Information
  51. 4.9.2 Pfizer, Inc. (US) Business Overview
  52. 4.9.3 Pfizer, Inc. (US) Overactive Bladder Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Pfizer, Inc. (US) Overactive Bladder Drug Product Portfolio
  54. 4.9.5 Pfizer, Inc. (US) Recent Developments
  55. 4.10 Mylan N.V. (US)
  56. 4.10.1 Mylan N.V. (US) Company Information
  57. 4.10.2 Mylan N.V. (US) Business Overview
  58. 4.10.3 Mylan N.V. (US) Overactive Bladder Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Mylan N.V. (US) Overactive Bladder Drug Product Portfolio
  60. 4.10.5 Mylan N.V. (US) Recent Developments
  61. 4.11 Sanofi (France)
  62. 4.11.1 Sanofi (France) Company Information
  63. 4.11.2 Sanofi (France) Business Overview
  64. 4.11.3 Sanofi (France) Overactive Bladder Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Sanofi (France) Overactive Bladder Drug Product Portfolio
  66. 4.11.5 Sanofi (France) Recent Developments
  67. 4.12 Teva Pharmaceutical Industries Limited (Israel)
  68. 4.12.1 Teva Pharmaceutical Industries Limited (Israel) Company Information
  69. 4.12.2 Teva Pharmaceutical Industries Limited (Israel) Business Overview
  70. 4.12.3 Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Product Portfolio
  72. 4.12.5 Teva Pharmaceutical Industries Limited (Israel) Recent Developments
5 Global Overactive Bladder Drug Market Scenario by Region
  1. 5.1 Global Overactive Bladder Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Overactive Bladder Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Overactive Bladder Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Overactive Bladder Drug Sales by Region: 2027-2032
  5. 5.3 Global Overactive Bladder Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Overactive Bladder Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Overactive Bladder Drug Revenue by Region: 2027-2032
  8. 5.4 North America Overactive Bladder Drug Market Facts & Figures by Country
  9. 5.4.1 North America Overactive Bladder Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Overactive Bladder Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Overactive Bladder Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Overactive Bladder Drug Market Facts & Figures by Country
  15. 5.5.1 Europe Overactive Bladder Drug Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Overactive Bladder Drug Sales by Country (2021-2032)
  17. 5.5.3 Europe Overactive Bladder Drug Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Overactive Bladder Drug Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Overactive Bladder Drug Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Overactive Bladder Drug Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Overactive Bladder Drug Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Overactive Bladder Drug Market Facts & Figures by Country
  35. 5.7.1 South America Overactive Bladder Drug Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Overactive Bladder Drug Sales by Country (2021-2032)
  37. 5.7.3 South America Overactive Bladder Drug Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Overactive Bladder Drug Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Overactive Bladder Drug Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Overactive Bladder Drug Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Overactive Bladder Drug Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Overactive Bladder Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Overactive Bladder Drug Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Overactive Bladder Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Overactive Bladder Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Overactive Bladder Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Overactive Bladder Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Overactive Bladder Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Overactive Bladder Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Overactive Bladder Drug Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Overactive Bladder Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Overactive Bladder Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Overactive Bladder Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Overactive Bladder Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Overactive Bladder Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Overactive Bladder Drug Value Chain Analysis
  2. 8.1.1 Overactive Bladder Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Overactive Bladder Drug Production Mode & Process
  5. 8.2 Overactive Bladder Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Overactive Bladder Drug Distributors
  8. 8.2.3 Overactive Bladder Drug Customers
9 Global Overactive Bladder Drug Analyzing Market Dynamics
  1. 9.1 Overactive Bladder Drug Industry Trends
  2. 9.2 Overactive Bladder Drug Industry Drivers
  3. 9.3 Overactive Bladder Drug Industry Opportunities and Challenges
  4. 9.4 Overactive Bladder Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst